Denali Therapeutics (DNLI) Share-based Compensation (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Share-based Compensation data on file, last reported at $23.1 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $23.1 million, down 8.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $97.6 million (down 2.63% YoY), and the FY2025 annual result was $99.6 million, down 3.15% from the prior year.
• Share-based Compensation retreated to $23.1 million in Q1 2026 per DNLI's latest filing, from $24.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $28.1 million in Q1 2023 and troughed at $23.1 million in Q1 2026.
• A 5-year average of $25.5 million and a median of $25.2 million in 2025 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation climbed 24.33% in 2022, then slipped 9.63% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $25.2 million in 2022, then advanced by 3.18% to $26.0 million in 2023, then slipped by 3.5% to $25.1 million in 2024, then slipped by 4.49% to $24.0 million in 2025, then dropped by 3.61% to $23.1 million in 2026.
• Business Quant data shows DNLI's Share-based Compensation at $23.1 million in Q1 2026, $24.0 million in Q4 2025, and $25.1 million in Q3 2025.